You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 169 No. 12, June 22, 2009 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Review Article
 •Online Features
 This Article
 •Full text
 •PDF
 •eTables
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Quality of Care
 •Evidence-Based Medicine
 •Quality of Life
 •Renal Diseases
 •Dialysis
 •Renal Diseases, Other
 •Review
 •Drug Therapy
 •Drug Therapy, Other
 •Hematology/ Hematologic Malignancies
 •Anemias
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease

A Systematic Review and Meta-analysis

Fiona M. Clement, PhD; Scott Klarenbach, MD, MSc; Marcello Tonelli, MD, SM; Jeffrey A. Johnson, PhD; Braden J. Manns, MD, MSc

Arch Intern Med. 2009;169(12):1104-1112.

Background  Treatment of anemia in chronic kidney disease (CKD) with erythropoietin-stimulating agents (ESAs) is commonplace. The optimal hemoglobin treatment target has not been established. A clearer understanding of the health-related quality of life (HQOL) impact of hemoglobin target levels is needed. We systematically reviewed the randomized controlled trial (RCT) data on HQOL for patients treated with low to intermediate (9.0-12.0 g/dL) and high hemoglobin target levels (>12.0 g/dL) and performed a meta-analysis of all available 36-item short-form (SF-36) RCT data.

Methods  We conducted a search to identify all RCTs of ESA therapy in patients with anemia associated with CKD (1966–December 2006). Inclusion criteria were (1) 30 or more participants, (2) anemic adults with CKD, (3) epoetin (alfa and beta) or darbepoetin used, (4) a control arm, and (5) reported HQOL using a validated measure. All available SF-36 data underwent meta-analysis using the weighted mean difference.

Results  Of 231 full texts screened, 11 eligible studies were identified. The SF-36 was used in 9 trials. Reporting of these data was generally incomplete. Data from each domain of the SF-36 were summarized. Statistically significant changes were noted in the physical function (weighted mean difference [WMD], 2.9; 95% confidence interval [CI], 1.3 to 4.5), general health (WMD, 2.7; 95% CI, 1.3 to 4.2), social function (WMD, 1.3; 95% CI, –0.8 to 3.4), and mental health (WMD, 0.4; 95% CI, 0.1 to 0.8) domains. None of the changes would be considered clinically significant.

Conclusions  Our study suggests that targeting hemoglobin levels in excess of 12.0 g/dL leads to small and not clinically meaningful improvements in HQOL. This, in addition to significant safety concerns, suggests that targeting treatment to hemoglobin levels that are in the range of 9.0 to 12.0 g/dL is preferred.


Author Affiliations: Departments of Community Health Sciences and Medicine and Centre for Health and Policy Studies, University of Calgary, Calgary, Alberta, Canada (Drs Clement and Manns); Department of Medicine, Division of Nephrology, University of Alberta, Edmonton (Drs Klarenbach and Tonelli); and Institute for Health Economics, Edmonton, Alberta (Dr Johnson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(12):1094.
FULL TEXT  

Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life
Shahriar Moossavi and Barry I. Freedman
Arch Intern Med. 2009;169(12):1100-1101.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients
Johansen et al.
Nephrol Dial Transplant 2011;0:gfr697v1-gfr697.
ABSTRACT | FULL TEXT  

Prevalence, characteristics and prognostic significance of anemia in daily practice
Terrier et al.
QJM 2011;0:hcr230v1-hcr230.
ABSTRACT | FULL TEXT  

Changes in quality of life over time--Dutch haemodialysis patients and general population compared
Mazairac et al.
Nephrol Dial Transplant 2011;26:1984-1989.
ABSTRACT | FULL TEXT  

Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease: A Randomized Trial
Lewis et al.
CJASN 2011;6:845-855.
ABSTRACT | FULL TEXT  

2009: A Requiem for rHuEPOs--But Should We Nail Down the Coffin in 2010?
Goldsmith
CJASN 2010;5:929-935.
ABSTRACT | FULL TEXT  

Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life
Moossavi and Freedman
Arch Intern Med 2009;169:1100-1101.
FULL TEXT  

All you need to read in the other general journals
BMJ 2009;338:b2511-b2511.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.